Navigation Links
Virobay Appoints David B. Karpf, M.D. as Chief Medicial Officer
Date:11/3/2011

Karpf joins Virobay from Metabolex, where he served as chief medical officer and vice president, clinical affairs. While at Metabolex, Dr. Karpf oversaw the development of four clinical programs spanning type 2 diabetes, dyslipidemia, and gout, including 2 INDs, 7 Phase 1 trials and 6 Phase 2 trials.  Prior to Metabolex, Dr. Karpf was executive director of clinical research and regulatory affairs at Geron where he provided oversight for Geron's early clinical programs in cancer and regenerative medicine.  Prior to Geron, Dr. Karpf was vice president, clinical and regulatory affairs at Calydon, Inc.  Prior to his tenure at Calydon, Dr. Karpf was executive director of clinical research at Roche Global Development in Palo Alto and was responsible for clinical development activities in metabolic bone disease and endocrinology, including managing the Phase 3 pivotal program for Boniva™.  Dr. Karpf was previously director of clinical research at Merck Research Laboratories in Rahway, New Jersey.  During his time at Merck he designed, monitored, and completed Phase 2, 3 and 4 clinical trials on Fosamax™ and played a pivotal role in the successful NDA and launch of this product.  In addition to his industry experience, Dr. Karpf has held several academic positions and is currently an adjunct clinical professor of endocrinology with the Stanford University School of Medicine, where he directs one of the endocrine subspecialty clinics.  He received his M.D. degree from University of California, San Diego, served on the fulltime endocrine faculty at UCSF School of Medicine, and has published numerous scientific papers and abstracts in the fields of endocrinology, bone disease, dyslipidemia and cancer.

About Virobay

Virobay is a leader in the design, synthesis and development of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases that are key mediators in a variety of diseases,
'/>"/>

SOURCE Virobay, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Axia Value Chain Appoints John Christina Managing Director of Life Sciences Practice
2. Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors
3. Metabolex Appoints Raymond Urbanski M.D., Ph.D. to Position of Chief Medical Officer
4. Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
5. Kessler Foundation Appoints New Director of Human Performance and Engineering Laboratory
6. China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee
7. Immune Design Corp. Appoints Guy F. Cipriani as Chief Business Officer
8. Amgen Appoints Robert A. Bradway to the Companys Board of Directors
9. PrimeraDx Appoints Jeff Liter as VP of Corporate Development
10. Oncobiologics Appoints Scott Canute, Former President of Eli Lilly and Genzyme, to its Board of Directors
11. PharmaVentures Appoints Andy Smith as Head of Corporate Finance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets  has announced the ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is ... or RNA) into cells. This technology helps the cells ... protein metabolism by affecting the nuclear genes. The transfection ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... (PCR) TECHNOLOGY: GLOBAL MARKETS , the global market for ... billion in 2013. This is estimated to grow to ... growth rate (CAGR) of 28.6%. , New digital PCR ... possibilities within the broader PCR field. The opportunities presented ...
(Date:7/11/2014)... EPFL and the University of  Geneva  (UNIGE) ... P. Donoghue . The American neuroscientist is to head ... The new Wyss Center for Bio- and Neuro-Engineering, ... , has named as its director one of the ... founder of Brown University,s Institute for Brain Science, has ...
(Date:7/11/2014)... ON , July 11, 2014 /CNW/ - Sunovion ... approved APTIOM TM (eslicarbazepine acetate) for use as ... seizures in patients with epilepsy who are not satisfactorily ... indicated for use in patients under 18 years of ... most common neurological disorders and according to Epilepsy Canada, ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4
... Mass. and WASHINGTON, Oct. 21 Boston,Scientific Corporation ... an analysis,of nearly 7,000 patients from its TAXUS ... performance of the TAXUS(R) Express2(TM) Paclitaxel-Eluting,Coronary Stent System ... low incidences of adverse events and repeat,revascularization through ...
... New Cases of Chagas, Disease ... & Blood Transfusions, ANAHEIM, Calif., Oct. 20 In ... the first blood-screening test,for Chagas, disease, some 241 blood donations ... the parasite known to cause,this serious and potentially fatal parasitic ...
... of AACR Virtual Meeting -, LOS ANGELES, Oct. ... announced that Kathleen Danenberg, the Company,s,President and Chief Executive ... in tailoring medicine at the 2007 AACR-NCI-EORTC,International Conference on ... 22-26, 2007 at the Moscone Convention Center,West in San ...
Cached Biology Technology:ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 2ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 4Blood Donations in U.S. Testing Positive for Chagas' Disease 2Blood Donations in U.S. Testing Positive for Chagas' Disease 3Blood Donations in U.S. Testing Positive for Chagas' Disease 4Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 2Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 3
(Date:7/10/2014)... July 9, 2014 The widespread adoption ... large part by meaningful use and related federal ... interact with laboratory information. Now, more than ever, ... of clinical informatics in order to deliver high ... address the educational needs of pathologists in this ...
(Date:7/10/2014)... The vegetable oil found in your popcorn or soap might ... get even worse, according to an analysis in the Cell ... The growing demand for vegetable oil has already led to ... bringing trouble for orangutans in particular. If guidelines are not ... those large-scale industrial plantations from Asia into Africa will be ...
(Date:7/10/2014)... The Marshall Institute for Interdisciplinary Research (MIIR) and ... Medicine today announced they will be partnering with ... drugs. , Under the agreement with Shanghai-based HD ... the costs and risks of discovery and development ... own any intellectual property and commercialization rights to ...
Breaking Biology News(10 mins):New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4Hunger for vegetable oil means trouble for Africa's great apes 2Marshall University to partner with international company in drug development venture 2
... nest boxes used to aid cavity-nesting ducks can prove to ... by University of Cincinnati Educator Associate Professor Denis Conover, of ... Arts and Sciences, when he came upon a duck nest ... The box had tipped over. Turtle corpses were strewn about ...
... The debate may largely be drawn along political lines, but ... most controversial questions in 21st century science. Writing in ... Center for Atmospheric Research, argues that the evidence for anthropogenic ... proof should lie with research which seeks to disprove the ...
... chilly inside your house, you might just turn the heater ... to a toastier and more comfortable state until it warms ... long thought cells would respond to their environment in a ... Institute of Technology (Caltech) are finding that cells can respond ...
Cached Biology News:UC research finds that a duck's boon might be a turtle's bane 2The human cause of climate change: Where does the burden of proof lie? 2Caltech researchers find pulsating response to stress in bacteria 2Caltech researchers find pulsating response to stress in bacteria 3
Hybridization Buffer 3.6 ml...
Olig2 Immunogen: Synthetic peptide from rat. Available Date: 9-19-2006...
Mouse monoclonal [0.N.305] to G protein alpha - BSA and Azide free ( Abpromise for all tested applications). Antigen: Partially purified G protein alpha from rat brain. Entrez GeneID: 2778 ...
Proteinase K Buffer 3.9 ml...
Biology Products: